REGN News and Press, Regeneron Pharmaceuticals Inc. From 05/03/24

2024-05-03 15:00:00 ET More on the markets My Current View Of The Market: May 2024 Edition (Technical Analysis) SPY: The 'Value' From Equities Is Historically Low SPY: The Setup Looks Extremely Bearish 'Sell in May and go away': Does it apply in 2024? ...

2024-05-03 14:15:02 ET UBS analyst issues BUY recommendation for REGN on May 3, 2024 12:00PM ET. The previous analyst recommendation was Buy. REGN was trading at $947.42 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst reco...

2024-05-02 12:28:13 ET Regeneron Pharmaceuticals, Inc. (REGN) Q1 2024 Earnings Conference Call May 02, 2024, 08:30 AM ET Company Participants Ryan Crowe - Senior Vice President, Investor Relations Leonard Schleifer - Board Co-Chair, Co-Founder, President & Chief ...

2024-05-02 09:11:00 ET U.S. stock index futures on Thursday pointed to a higher open, a day after the Federal Reserve and chair Jerome Powell were widely perceived to be much more dovish than expected. Here are some stocks to watch on Thursday: ... Read the full article on Se...

2024-05-02 07:55:40 ET More on Regeneron Pharmaceuticals Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners Global Biopharma Conference (Transcript) Regeneron Pharmaceuticals, Inc. (REGN) Barclays ...

2024-05-02 07:15:00 ET The phrase "the golden age of biotech" was somewhat popular a few years ago but now seems largely forgotten. Regardless, biotech companies can be excellent long-term investment options for several reasons. Many are highly innovative corporations that develop break...

2024-05-02 06:32:10 ET More on Regeneron Pharmaceuticals Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate Regeneron, Mammoth in pact to develop CRISPR-based gene editing therapies Read the full article on Seeking Alpha For further details see:...

2024-05-01 13:18:37 ET More on Adverum Biotechnologies Seeking Alpha’s Quant Rating on Adverum Biotechnologies Historical earnings data for Adverum Biotechnologies Financial information for Adverum Biotechnologies Read the full article on Seeking Alp...

2024-05-01 11:30:13 ET More on Regeneron Pharmaceuticals Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners Global Biopharma Conference (Transcript) Regeneron Pharmaceuticals, Inc. (REGN) Barclays ...

TARRYTOWN, N.Y., April 29, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the presentation of positive long-term results and subgroup analyses from the pivotal clinical program of EYLEA ® HD (aflibercept) Injection 8 mg. The presentations are part...